Clinical Trial Detail

NCT ID NCT03804944
Title Converting HR+ Breast Cancer Into an Individualized Vaccine (CBCV)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Weill Medical College of Cornell University
Indications

Her2-receptor negative breast cancer

Therapies

CDX-301

CDX-301 + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.